Interestingly, ASH1L-AS1 expression could also be used to differentiate patients in complete remission status and those with preliminary diagnosis, further supporting the status of ASH1L-AS1 and APPLE as predictors of poor AML prognosis [17]. This evidence concerns the gene ASH1L and acute myeloid leukemia.